At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
AMD11070drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IB/IIA Dose-Finding Safety and Activity Study of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor) in HIV-Infected Subjects
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 6, 2004·Updated Nov 9, 2021
In Brief
A Phase 2 clinical trial evaluating AMD11070 for HIV Infections. Completed, enrolled 6 participants across 3 sites.
Detailed Summary
New treatment options are critical for treatment-experienced HIV infected patients with drug resistance. HIV entry inhibitors have been shown effective in patients with resistance to other anti-HIV drugs. This study will test the safety and anti-HIV activity of eight different doses of the HIV entry inhibitor AMD11070 (also known as AMD070) in HIV infected patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2004
Enrollment StartNov 2004
Primary CompletionJun 2006
Study CompletionJan 2009
TodayJul 2026
First PostedAug 6, 2004
Enrollment StartNov 1, 2004
Primary CompletionJun 1, 2006
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 21.9 years ago
Interventions
AMD11070drug
AMD11070 taken daily. Dosage dependent on arm.